Loading...

Mainz Biomed B.V.

MYNZ•NASDAQ
Healthcare
Medical - Diagnostics & Research
$2.04
$0.05(2.51%)

Mainz Biomed B.V. (MYNZ) Company Profile & Overview

Explore Mainz Biomed B.V.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Mainz Biomed B.V. (MYNZ) Company Profile & Overview

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

SectorHealthcare
IndustryMedical - Diagnostics & Research
CEOGuido Baechler

Contact Information

https://mainzbiomed.com
49 6131 554 2860
Robert Koch Strasse 50, Mainz, 55129

Company Facts

19 Employees
IPO DateNov 5, 2021
CountryDE
Actively Trading

Frequently Asked Questions

;